Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Battat

Showing results (21-30 of 95) with videos related to

Pageof 10
Sort By:
Drug Safety|March 5, 2019
Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative ColitisRobert Battat, Christopher Ma, Vipul Jairath, et al.
Molecular Cancer|August 7, 2009
Transcriptional activation of the Lats1 tumor suppressor gene in tumors of CUX1 transgenic miceRania Siam, Ryoko Harada, Chantal Cadieux, et al.
Digestive Diseases and Sciences|September 20, 2014
Hematologic indices as surrogate markers for monitoring thiopurine therapy in IBDUri Kopylov, Robert Battat, Amine Benmassaoud, et al.
Best Practice & Research. Clinical Gastroenterology|July 23, 2019
What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?Christopher Ma, Robert Battat, Reena Khanna, et al.
Expert Review of Gastroenterology & Hepatology|February 23, 2019
Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn's disease?Christopher Ma, Robert Battat, Claire E Parker, et al.
World Journal of Gastroenterology|September 29, 2016
Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review articleChe-Yung Chao, Robert Battat, Alex Al Khoury, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 13, 2021
Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 VaccinationParis Charilaou, Christopher Tricarico, Robert Battat, et al.
The American Journal of Managed Care|October 16, 2023
Real-world impact of infliximab precision-guided dosing on management of patients with IBDBincy P Abraham, David A Ziring, Thierry Dervieux, et al.
Journal of Clinical Medicine|November 14, 2023
Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel DiseaseRochelle Wong, Lihui Qin, Yushan Pan, et al.
Journal of Gastroenterology|May 6, 2020
Defining the phenotype, pathogenesis and treatment of Crohn's disease associated spondyloarthritisAnand Kumar, Dana Lukin, Robert Battat, et al.
Pageof 10

Showing results (21-30 of 95) with videos related to

Sort By:
Pageof 10
Drug Safety|March 5, 2019
Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative ColitisRobert Battat, Christopher Ma, Vipul Jairath, et al.
Molecular Cancer|August 7, 2009
Transcriptional activation of the Lats1 tumor suppressor gene in tumors of CUX1 transgenic miceRania Siam, Ryoko Harada, Chantal Cadieux, et al.
Digestive Diseases and Sciences|September 20, 2014
Hematologic indices as surrogate markers for monitoring thiopurine therapy in IBDUri Kopylov, Robert Battat, Amine Benmassaoud, et al.
Best Practice & Research. Clinical Gastroenterology|July 23, 2019
What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?Christopher Ma, Robert Battat, Reena Khanna, et al.
Expert Review of Gastroenterology & Hepatology|February 23, 2019
Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn's disease?Christopher Ma, Robert Battat, Claire E Parker, et al.
World Journal of Gastroenterology|September 29, 2016
Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review articleChe-Yung Chao, Robert Battat, Alex Al Khoury, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 13, 2021
Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 VaccinationParis Charilaou, Christopher Tricarico, Robert Battat, et al.
The American Journal of Managed Care|October 16, 2023
Real-world impact of infliximab precision-guided dosing on management of patients with IBDBincy P Abraham, David A Ziring, Thierry Dervieux, et al.
Journal of Clinical Medicine|November 14, 2023
Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel DiseaseRochelle Wong, Lihui Qin, Yushan Pan, et al.
Journal of Gastroenterology|May 6, 2020
Defining the phenotype, pathogenesis and treatment of Crohn's disease associated spondyloarthritisAnand Kumar, Dana Lukin, Robert Battat, et al.
Pageof 10